Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-019C in Relapse/Refractory Autoimmune Diseases
NCT07315087Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-CD19/BCMA CAR T-cells in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and 2 more, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Adverse Events at 12 months. Started Jan 2026; status: recruiting.
02
Drugs
anti-CD19/BCMA CAR T-cells
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)idiopathic inflammatory myopathy (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)Thrombocytopenia
Beyond the preview
Go deeper on NCT07315087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07315087.